{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:23:44Z","timestamp":1789093424791,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.arr.2022.101670","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:39:26Z","timestamp":1655437166000},"page":"101670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Beta-adrenergic drugs and risk of Parkinson\u2019s disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"80","author":[{"given":"Ambrish","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelatha","family":"Akkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Klugarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pokorn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Klugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Haydn","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16 Part 2","key":"10.1016\/j.arr.2022.101670_bib1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2022.101670_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/164_2016_64","article-title":"Hall IP. \u03b2(2) Agonists","volume":"237","author":"Billington","year":"2017","journal-title":"Handb. Exp. Pharm."},{"issue":"5","key":"10.1016\/j.arr.2022.101670_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/phar.2383","article-title":"Effects of \u03b22-Adrenergic Agonists on Risk of Parkinson\u2019s Disease in COPD: A Population-Based Study","volume":"40","author":"Chen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.arr.2022.101670_bib4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/all.12758","article-title":"Risk of developing Parkinson\u2019s disease among patients with asthma: a nationwide longitudinal study","volume":"70","author":"Cheng","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.arr.2022.101670_bib5","unstructured":"Cochrane C. Review manager (version 5.4.1)[computer software]. The Cochrane Collaboration: Copenhagen, Denmark. 2014."},{"key":"10.1016\/j.arr.2022.101670_bib6","doi-asserted-by":"crossref","unstructured":"Collaborators. GPsD. Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u2013953.","DOI":"10.1016\/S1474-4422(18)30295-3"},{"key":"10.1016\/j.arr.2022.101670_bib7","unstructured":"Covidence2021. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia."},{"issue":"7136","key":"10.1016\/j.arr.2022.101670_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bmj.316.7136.989","article-title":"When can odds ratios mislead?","volume":"316","author":"Davies","year":"1998","journal-title":"Bmj"},{"issue":"8","key":"10.1016\/j.arr.2022.101670_bib9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.arr.2022.101670_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bcp.12705","article-title":"Indication bias or protopathic bias?","volume":"80","author":"Faillie","year":"2015","journal-title":"Br. J. Clin. Pharm."},{"issue":"4","key":"10.1016\/j.arr.2022.101670_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40471-014-0027-z","article-title":"Misclassification in administrative claims data: quantifying the impact on treatment effect estimates","volume":"1","author":"Funk","year":"2014","journal-title":"Curr. Epidemiol. Rep."},{"issue":"7","key":"10.1016\/j.arr.2022.101670_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40263-020-00736-2","article-title":"\u03b2-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study","volume":"34","author":"de Germay","year":"2020","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.arr.2022.101670_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/aje\/kwaa012","article-title":"\u03b2 2-Agonists and the Incidence of Parkinson Disease","volume":"189","author":"Giorgianni","year":"2020","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.arr.2022.101670_bib14","unstructured":"Global burden of disease 2019 disease i, and impairment summaries;. Parkinson's disease\u2014Level 3 cause. Institute for Health Metrics and Evaluation. http:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/parkinsons-disease-level-3-cause.Published 2019. Accessed 01 June 2021, 2021."},{"issue":"9","key":"10.1016\/j.arr.2022.101670_bib15","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov. Disord."},{"issue":"7454","key":"10.1016\/j.arr.2022.101670_bib16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Group","year":"2004","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.arr.2022.101670_bib17","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/WNL.0000000000007694","article-title":"Use of \u03b22-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease","volume":"93","author":"Hopfner","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.arr.2022.101670_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(19)30400-4","article-title":"\u03b2-adrenoreceptors and the risk of Parkinson\u2019s disease","volume":"19","author":"Hopfner","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.arr.2022.101670_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40261-019-00771-y","article-title":"Chronic use of \u03b2-blockers and the risk of Parkinson\u2019s disease","volume":"39","author":"Koren","year":"2019","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.arr.2022.101670_bib20","series-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU)","article-title":"Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis","author":"Kouli","year":"2018"},{"issue":"3","key":"10.1016\/j.arr.2022.101670_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson\u2019s disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.arr.2022.101670_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijcard.2012.03.085","article-title":"No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis","volume":"167","author":"Kwok","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.arr.2022.101670_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098961","article-title":"Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.arr.2022.101670_bib24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Antihypertensive agents and risk of Parkinson\u2019s disease, essential tremor and dementia: a population-based prospective study (NEDICES)","volume":"33","author":"Louis","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.arr.2022.101670_bib25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1533317513488919","article-title":"The role of \u03b2-adrenergic blockers in parkinson\u2019s Disease: Possible genetic and cell-signaling mechanisms","volume":"28","author":"L\u01b0\u01a1ng","year":"2013","journal-title":"Am. J. Alzheimer\u2019S. Dis. Other Dementias\u00ae"},{"issue":"1","key":"10.1016\/j.arr.2022.101670_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/emj.20.1.54","article-title":"Observational research methods. Research design II: cohort, cross sectional, and case-control studies","volume":"20","author":"Mann","year":"2003","journal-title":"Emerg. Med J."},{"issue":"6354","key":"10.1016\/j.arr.2022.101670_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.arr.2022.101670_bib28","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ","volume":"372","author":"Page","year":"2021","journal-title":"372"},{"key":"10.1016\/j.arr.2022.101670_bib29","first-page":"3","article-title":"Identifying incident Parkinson\u2019s disease using administrative diagnostic codes: a validation study","volume":"3","author":"Peterson","year":"2020","journal-title":"Clin. Park Relat. Disord."},{"issue":"1","key":"10.1016\/j.arr.2022.101670_bib30","first-page":"1","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"13","key":"10.1016\/j.arr.2022.101670_bib31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.arr.2022.101670_bib32","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.4049\/jimmunol.1002449","article-title":"\u03b22-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway","volume":"186","author":"Qian","year":"2011","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.arr.2022.101670_bib33","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1073\/pnas.81.5.1585","article-title":"Quantitative autoradiography of beta 1- and beta 2-adrenergic receptors in rat brain","volume":"81","author":"Rainbow","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.arr.2022.101670_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000135","article-title":"Chronic heavy drinking and ischaemic heart disease: a systematic review and meta-analysis","volume":"1","author":"Roerecke","year":"2014","journal-title":"Open Heart"},{"issue":"4","key":"10.1016\/j.arr.2022.101670_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cells8040357","article-title":"Everything you always wanted to know about \u03b2(3)-AR * (* but were afraid to ask)","volume":"8","author":"Schena","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.arr.2022.101670_bib36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"\u03b22-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2022.101670_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2021.01.018","article-title":"Association of beta-2-microglobulin and cardiovascular events and mortality: A systematic review and meta-analysis","volume":"320","author":"Shi","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arr.2022.101670_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jns.2017.09.026","article-title":"Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis","volume":"381","author":"Singh","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2022.101670_bib39","doi-asserted-by":"crossref","unstructured":"Singh A., Hussain S., Akkala S., et al. Systematic Review and Meta-Analysis Protocol: Beta adrenoreceptor drugs and risk of Parkinson\u2019s disease. medRxiv. 2021:2021.2005.2019.21257436.","DOI":"10.1101\/2021.05.19.21257436"},{"key":"10.1016\/j.arr.2022.101670_bib40","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/j.jval.2018.09.1969","article-title":"Risk of Parkinson\u2019s disease (PD) in patients taking adrenergic drug treatments","volume":"21","author":"Stacey","year":"2018","journal-title":"Value Health"},{"issue":"15","key":"10.1016\/j.arr.2022.101670_bib41","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"issue":"2\u20133","key":"10.1016\/j.arr.2022.101670_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/CRIAI:31:2:107","article-title":"Current issues with beta2-adrenoceptor agonists: historical background","volume":"31","author":"Tattersfield","year":"2006","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.arr.2022.101670_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.arr.2022.101670_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson\u2019s disease","volume":"13","author":"Ton","year":"2007","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2022.101670_bib45","unstructured":"Van Laar AKM, Zharikov A. Pharmacogenomic repression of alpha-synuclein with beta2 adrenoreceptor agonist is protective in a new rotenone model of delayed, progressive Parkinson's disease. Society for Neuroscience. \u3008https:\/\/www.abstractsonline.com\/pp8\/#!\/4649\/presentation\/37962\u3009. Published 2018. Accessed2021."},{"issue":"1","key":"10.1016\/j.arr.2022.101670_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mds.27586","article-title":"From beta\u2010blockers to Parkinson\u2019s disease in respect of essential tremor","volume":"34","author":"Vogelnik","year":"2019","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.arr.2022.101670_bib47","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ije\/dyx253","article-title":"comparison of methods to correct for misclassification bias from administrative database diagnostic codes","volume":"47","author":"Walraven","year":"2018","journal-title":"Int. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.arr.2022.101670_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5414\/CP203559","article-title":"The association between antihypertensive therapy and the incidence of Parkinson\u2019s disease in patients followed in general practices in Germany","volume":"57","author":"Warda","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156816372200112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156816372200112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:03:03Z","timestamp":1761591783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156816372200112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":48,"alternative-id":["S156816372200112X"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2022.101670","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.19.21257436","asserted-by":"object"}]},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-adrenergic drugs and risk of Parkinson\u2019s disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2022.101670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101670"}}